848092-84-2

Basic information

• Product Name: methyl 2-amino-4-hydroxy-5-methoxybenzoate
• Synonyms: methyl 2-amino-4-hydroxy-5-methoxybenzoate
• CAS NO: 848092-84-2
• Molecular Formula: C₉H₁₁NO₄
• Molecular Weight: 197.18794
• Mol File: 848092-84-2.mol
• Article Data: 14

Chemical Properties

• Appearance: /
• CAS DataBase Reference: methyl 2-amino-4-hydroxy-5-methoxybenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 2-amino-4-hydroxy-5-methoxybenzoate(848092-84-2)
• EPA Substance Registry System: methyl 2-amino-4-hydroxy-5-methoxybenzoate(848092-84-2)

Safety Data

• Hazardous Substances Data: 848092-84-2(Hazardous Substances Data)

Upstream product

• 3943-74-6 4-hydroxy-3-methoxybenzoic acid methyl ester 
• 27883-60-9 4-hydroxy-5-methoxy-2-nitrobenzoic acid methyl ester 
• 56441-97-5 methyl 4-(benzyloxy)-3-methoxybenzoate 
• 61032-41-5 methyl 4-(benzyloxy)-5-methoxy-2-nitrobenzoate 

Downstream Products

• 179688-03-0 4-chloro-6-methoxyquinazolin-7-yl acetate 
• 179688-02-9 7-acetoxy-6-methoxy-3,4-dihydroquinazolin-4-one 

Relevant articles and documents

HISTONE METHYLTRANSFERASE INHIBITORS

The present disclosure provides certain compounds of formula (I) that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinpathies such as beta-thalassemia and sickle cell disease. Also provided are pharmaceutical compositions containing such compounds as well as processes and intermediates for preparing such compounds.

CONJUGATES FOR TREATING DISEASES

The present disclosure relates to pyrrolobenzodiazepine (PBD) prodrugs and conjugates thereof. The present disclosure also relates to pharmaceutical compositions of the conjugates described herein, methods of making and methods of using the same.

Substituted 2-arylbenzothiazoles as kinase inhibitors: Hit-to-lead optimization

Based on an (aminoaryl)benzothiazole quinazoline hit structure for kinase inhibition, a systematic optimization program resulted in a lead structure allowing for inhibitory activities in cellular phosphorylation assays in the low nanomolar range.